Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Bonelli, RM; Hodl, AK; Kapfhammer, HP.
Neuroprotection in Huntington's disease
LETT DRUG DES DISCOV. 2005; 2: 143-147.
Doi: 10.2174/1570180053175133
Web of Science
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Bonelli Raphael
- Co-authors Med Uni Graz
- Holl Anna
- Kapfhammer Hans-Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Minocycline, the 7-dimethylamino- 6-dimethyl-desoxytetracycline hydrochloride, is a caspase-1 inhibitor and may serve as anti-apoptotic agent, thereby acting neuroprotective. It directly inhibits both caspase-independent and -dependent mitochondrial cell death pathways, and decreases inducible nitric oxide synthetase activity. Minocycline delays disease progression in the transgenic mouse model of Huntington's disease (HD), extending survival by 14%. HD is a late onset relentlessly progressive, neurodegenerative disorder with currently no cures or even effective therapies, death occurring 15 years after onset. In this review, recent clinical and preclinical data on minocycline in HD and neuroprotective alternatives discussed.